Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.


Investor type Private Equity Firm
Founders Gerhard Ries


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 79
Average round size
The average size of a deal this fund participated in
Portfolio companies 46
Rounds per year 4.16
Lead investments 20
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 19
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical Device
  • Medical

The venture was found in Europe in Switzerland. The main office of represented VC is situated in the Basel.

The fund was created by Gerhard Ries. We also calculated 4 valuable employees in our database.

The fund has exact preference in a number of founders of portfolio startups. If startup sums 3 of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight Anergis, Inotrem, Miracor Medical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Developer Platform, Health Care. For fund there is a match between the location of its establishment and the land of its numerous investments - Switzerland.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 deals per year. This BioMedPartners works on 0 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2014. Considering the real fund results, this VC is 12 percentage points more often commits exit comparing to other organizations.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the BioMedPartners, startups are often financed by Novartis Venture Fund, High-Tech Gru00fcnderfonds, KfW. The meaningful sponsors for the fund in investment in the same round are Novartis Venture Fund, BB Biotech Ventures, Neomed Management. In the next rounds fund is usually obtained by SV Health Investors, Novartis Venture Fund, HBM Healthcare Investments AG.

Read more

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ImmunOs Therapeutics

Drug Discovery
Health Care
$77M07 Jun 2022 Zurich, Switzerland


Health Care
Life Science
$70M03 May 2022 Munich, Bavaria, Germany


$94M16 Mar 2022 City of Brussels, Belgium

Scenic Biotech

Collaborative Consumption
Life Science
$33M10 Mar 2022 Amsterdam, North Holland, Netherlands

Cardior Pharmaceuticals

$75M25 Aug 2021 Hanover, Lower Saxony, Germany

Topas Therapeutics

Advanced Materials
Chemical Engineering
$21M29 Jul 2021 Germany, Baden-Württemberg, Germany

Alentis Therapeutics

$65M15 Jun 2021 Basel, Basel-City, Switzerland

Noema Pharma

$58M01 Dec 2020 Basel, Basel-City, Switzerland

Topas Therapeutics

Advanced Materials
Chemical Engineering
$25M19 Oct 2020 Baden-Württemberg
Cardior Raises €64M in Series B Funding

– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.

Alentis Therapeutics Raises $67M in Series B Financing

– Alentis Therapeutics from Basel develops new treatments for fibrotic diseases.
– The company raised $67m in Series B financing round.
– The round was led by Morningside Venture Investments, joined by Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital.
– The new investment will be used to support the company’s drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BioMedPartners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: